glp-1/gip/glucagon receptor agonist Review Article: GLP‐1 Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD retatrutide triple agonist gip glp-1

372 Linderstrom-LangK

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8

Total awareness is now up to 80%, which sounds a lot like saturation

ALCAR is a natural neurotrophic compound currently marketed for the treatment of neuropathies

While this may provide localized antioxidant support, glutathione is a large molecule that does not easily penetrate the deeper layers of the skin where melanin is produced

People with diabetes, insulin resistance, or pre-diabetes need to monitor closely